osimertinib
astrazeneca
['sclc', 'osimertinib', 'nsclc']
adjuvant osimertinib provided a significant overall survival benefit among patients with completely resected, egfr-mutated, stage ib to iiia nsclc. #asco23 #asco2023 
Biomedical Science that Inspires. #medicine #medtwitter #meded #Science #Research #Technology #News